<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">Co...

SMMT

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

Ivonescimab OS reads strengthen data; FDA filing and cash runway extended

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot; class=&quot;bwalignc&quot;&gt;
&lt;i xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;Co...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Summit reported Q2 results with $690.7M cash and ATM proceeds totaling $299.2M, extending financing runway. ASCO readouts for HARMONi-6 and updated HARMONi OS show cross-population survival benefits, and the FDA accepted the ivonescimab BLA with a PDUFA of 11/14/2026, creating near-term catalysts. A complete HARMONi-3 readout and continued international development support upside.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>HARMONi-6 OS readout: ivonescimab+chemo beats tislelizumab+chemo; HR 0.66.</li><li>Updated HARMONi OS in Western patients aligns with Asian results; HR 0.76.</li><li>FDA accepted for filing BLA for ivonescimab in EGFRm NSCLC; PDUFA 11/14/2026.</li><li>Q2 2026 cash: $690.7M; ATM raises $230.8M in Q2, $68.4M post.</li><li>HARMONi-3 enrollment complete; PFS events due 2H2026; OS interim 1H2027.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Akeso Inc. (9926.HK)</strong>: Ivonescimab originated in Akeso; Summit has exclusive rights in major regions; collaboration backdrop supports global trials.</li><li><strong>Arcus Biosciences (RCUS)</strong>: Collaborating with Summit to evaluate ivonescimab with Arcus’ casdatifan; data by mid-2027.</li><li><strong>Revolution Medicines (RVMD)</strong>: Part of RevMed collaboration to test ivonescimab with RAS(ON) inhibitors; enrollment began 2026.</li><li><strong>GSK plc (GSK)</strong>: Collaborating to evaluate ivonescimab with risvutatug rezetecan; dosing to begin later this quarter.</li><li><strong>BeiGene Ltd (BGNE)</strong>: Tislelizumab comparator; competitive PD-(L)1 landscape relevant to HARMONi-6 results.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The release combines Phase III trial updates and a major regulatory milestone, which are core corporate development catalysts for SMMT.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>FDA accepts BLA for ivonescimab; PDUFA date set for Nov 14, 2026.</li><li>HARMONi-6 OS HR 0.66; first head-to-head OS benefit vs anti-PD-(L)1.</li><li>Western vs Asian OS consistency: HR 0.76 in updated analysis.</li><li>Cash runway extended: $690.7M; ATM proceeds totaling $299.2M.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Cash and cash equivalents and short-term investments: $690.7 million as of June 30, 2026.</li><li>Dec 31, 2025 cash and investments: $713.4 million.</li><li>HARMONi-6 OS hazard ratio: 0.66 (95% CI 0.50-0.87; p=0.0017).</li><li>FDA accepted for filing ivonescimab BLA for EGFR-mutated NSCLC; PDUFA 11/14/2026.</li><li>HARMONi-3 enrollment complete; squamous/non-squamous PFS events expected 2H2026; OS interim 1H2027.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish into 4Q26–1H27 on FDA decision, BLA progress, and OS readouts.</p>
  </section>
</section>


<article>
  <h1>Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026</h1>

  <section aria-labelledby="overview">
    <h2 id="overview">Overview and Key Developments</h2>
    <p>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SMMT">SMMT</a>) today reported its financial results for the second quarter and six months ended June 30, 2026 and provided an update on clinical and operational progress.</p>
    <p>Two data readouts from the ivonescimab program underscore ongoing development momentum: the HARMONi-6 Phase III trial in first-line NSCLC demonstrated the first head-to-head Phase III study in any tumor type to show a meaningful overall survival advantage in combination with chemotherapy against an anti-PD-(L)1 antibody-containing regimen, a milestone for cancer patients and the broader immuno-oncology field. Updated OS data from the HARMONi trial showed western patients replicated the survival benefit seen in Asian patients, reinforcing confidence in geographic consistency of ivonescimab efficacy across populations.</p>
  </section>

  <section aria-labelledby="financial-highlights">
    <h2 id="financial-highlights">Financial Highlights and Cash Position</h2>
    <p>In connection with the quarter, Summit reported its cash and investment position as of June 30, 2026, reflecting liquidity the company continues to deploy to advance ivonescimab and its broader development program.</p>
    <ul>
      <li><strong>Cash and investments:</strong> $690.7 Million as of June 30, 2026.</li>
    </ul>
  </section>

  <section aria-labelledby="quotes-section">
    <h2 id="quotes-section">Leadership Commentary on Clinical Momentum</h2>
    <p>"The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningful overall survival advantage over anti-PD-1 inhibitors in combination with chemotherapy, representing an important milestone for cancer patients and for the broader immuno-oncology field," said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit. "This was followed by updated overall survival data from the HARMONi trial, in which western patients replicated the survival benefit seen in Asian patients and further reinforces our confidence in the regional consistency of the efficacy results of ivonescimab."</p>
    <p>"These new data continue to demonstrate the differentiated profile of ivonescimab," said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit. "In HARMONi-6, we saw an outcome that underscores the potential impact of our bispecific PD-1 / VEGF program. Equally important, the updated HARMONi overall survival analysis provided additional evidence of consistency of efficacy outcomes across patient populations. We also presented encouraging Phase II colorectal cancer data at ASCO that adds to the growing body of evidence supporting the potential of ivonescimab as a differentiated PD-1 / VEGF bispecific antibody across tumor types. We believe these results meaningfully strengthen the overall body of evidence supporting ivonescimab and provide important validation as we advance our global development program across multiple solid tumors."</p>
  </section>

  <section aria-labelledby="clinical-updates">
    <h2 id="clinical-updates">Clinical &amp; Operational Updates</h2>
    <p>Clinical and operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule:</p>
    <ul class="bwlistdisc">
      <li>Summit in-licensed ivonescimab from Akeso Inc. (Akeso, HKEX Code: 9926.HK) in January 2023. In total, over 4,000 patients have been treated with ivonescimab in clinical studies globally, and over 70,000 patients have been treated in the commercial setting with ivonescimab in China, as noted and updated by Akeso. Summit has exclusive rights to develop and commercialize ivonescimab in North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso retains development and commercialization rights for remaining territories, including China.</li>
      <li>Summit is developing ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), specifically conducting multiregional Phase III clinical trials in the following proposed indications:
        <ul class="bwlistcircle">
          <li>HARMONi: Ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR tyrosine kinase inhibitor (TKI);</li>
          <li>HARMONi-3: Ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors;</li>
          <li>HARMONi-7: Ivonescimab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression; and</li>
          <li>HARMONi-GI3: Ivonescimab combined with chemotherapy in patients with first-line unresectable metastatic CRC.</li>
        </ul>
      </li>
    </ul>

    <p><span class="bwuline">HARMONi</span></p>

    <ul class="bwlistdisc">
      <li>In January 2026, the U.S. Food and Drug Administration (FDA) accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have received prior EGFR TKI therapy. The BLA was submitted based on the overall results of the global Phase III HARMONi trial. The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.</li>
      <li>In July 2026, Summit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsmmttx.com%2Fnews%2Fpress-releases%2Fnews-details%2F2026%2FIvonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study%2Fdefault.aspx&amp;esheet=54576217&amp;newsitemid=20260723317187&amp;lan=en-US&amp;anchor=announced&amp;index=1&amp;md5=4386f42a5f934f252221849d8f5be289" shape="rect">announced</a> results of a new updated overall survival (OS) analysis from the HARMONi study, which showed a consistent OS trend amongst western and Asian patients as western patients were followed for additional time on study. These encouraging results provide further evidence of the geographic translatability of ivonescimab across the globe, including western patients from North America and Europe. In this new analysis, western patients increased their time on study, reaching a median follow-up of 23.2 months; Asian patients remained locked with a median follow-up time of 32.7 months. A hazard ratio of 0.76 was observed for the full ITT population; the same 0.76 hazard ratio was observed in both Asian and western patient subgroups, respectively, in this analysis. Ivonescimab continued to demonstrate an acceptable and manageable safety profile that was consistent with previous Phase III data of ivonescimab plus chemotherapy. No additional safety signals were observed. These results have been made available to the FDA...</li>
    </ul>
  </section>

  <section aria-labelledby="harmoni-background">
    <h2 id="harmoni-background">HARMONi Program Background and Global Development Plan</h2>
    <p>The HARMONi program represents Summit's multiregional Phase III clinical program evaluating ivonescimab in NSCLC and CRC, with multiple cohorts and combinations designed to assess efficacy across tumor types and geographies. The program emphasizes a PD-1 / VEGF bispecific approach intended to leverage immunotherapy with anti-angiogenesis in a single molecule.</p>
  </section>

  <section aria-labelledby="regulatory-update">
    <h2 id="regulatory-update">Regulatory Updates and U.S. FDA Interactions</h2>
    <ul class="bwlistdisc">
      <li><strong>FDA BLA acceptance:</strong> In January 2026, the FDA accepted for filing Summit's BLA seeking approval for ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have received prior EGFR TKI therapy. The BLA was submitted based on the overall results of the global Phase III HARMONi trial. The FDA provided a PDUFA goal action date of November 14, 2026.</li>
      <li><strong>Regulatory readouts:</strong> In July 2026, Summit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fsmmttx.com%2Fnews%2Fpress-releases%2Fnews-details%2F2026%2FIvonescimab-Plus-Chemotherapy-Shows-Consistent-Favorable-Overall-Survival-Results-in-Western-and-Asian-Patients-in-Updated-Analysis-from-Global-Phase-III-HARMONi-Study%2Fdefault.aspx&amp;esheet=54576217&amp;newsitemid=20260723317187&amp;lan=en-US&amp;anchor=announced&amp;index=1&amp;md5=4386f42a5f934f252221849d8f5be289" shape="rect">announced</a> results of a new updated OS analysis from the HARMONi study...</li>
    </ul>
  </section>

  <section aria-labelledby="about-summit">
    <h2 id="about-summit">About Summit and Ivonescimab</h2>
    <p>Summit Therapeutics Inc. is advancing ivonescimab (SMT112), a bispecific antibody designed to combine PD-1 blockade with VEGF inhibition. The company holds exclusive development and commercialization rights in major regions outside China, where Akeso retains certain rights.</p>
  </section>
</article>

Summit reported Q2 results with $690.7M cash and ATM proceeds totaling $299.2M, extending financing runway. ASCO readouts for HARMONi-6 and updated HARMONi OS show cross-population survival benefits, and the FDA accepted the ivonescimab BLA with a PDUFA of 11/14/2026, creating near-term catalysts. A complete HARMONi-3 readout and continued international development support upside.

News insight

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026

AI summary

Sentiment rationale

Key facts

Corporate Developments